. Author manuscript; available in PMC: 2021 Oct 1.

Published in final edited form as: Lancet Haematol. 2020 Oct;7(10):e715–e723. doi: 10.1016/S2352-3026(20)30294-5

Table 2:

Risk of non-relapse mortality and overall survival in relation to donor IFNL4 genotype

	Non-relapse Mortality (NRM)		Overall Survival (OS)
	N^a events/total	HR^b (95% CI) P-value	N events/total	HR^b (95% CI) P-value
Discovery NCI set^c (N=404)
IFNL4 genotype (per risk allele)^d	115/402	1.60 (1.23–2.10) 0.0005	223/404	1.24 (1.02–1.51) 0.03
IFN-λ4 protein status
IFN-λ4-Null	38/177	reference	91/177	reference
IFN-λ4-Weak	14/55	1.32 (0.71–2.48) 0.38	30/56	1.06 (0.69–1.62) 0.79
IFN-λ4-Strong	62/169	2.18 (1.43–3.30) 0.0002	101/170	1.39 (1.04–1.86) 0.03
DBMT validation set^c (N=1245)
IFNL4 genotype (per risk allele)^d	407/1244	1.22 (1.05–1.41) 0.007	875/1245	1.10 (0.98–1.20) 0.10
IFN-λ4 protein status
IFN-λ4-Null	165/556	reference	390/556	reference
IFN-λ4-Weak	50/163	1.07 (0.77–1.47) 0.6	112/163	1.01 (0.82–1.2) 0.86
IFN-λ4-Strong	191/521	1.29 (1.05–1.60) 0.01	371/522	1.08 (0.93–1.24) 0.28
DBMT full set (overlapping + validation; N=1593)
IFNL4 genotype (per risk allele)^d	518/1591	1.27 (1.12–1.45) 0.0001	1078/1593	1.11 (1.02–1.22) 0.02
IFN-λ4 protein status
IFN-λ4-Null	211/720	reference	482/720	reference
IFN-λ4-Weak	65/212	1.11 (0.84–1.47) 0.44	140/212	1.03 (0.85–1.25) 0.70
IFN-λ4-Strong	241/655	1.37 (1.14–1.65) 0.0007	454/657	1.13 (0.99–1.28) 0.06

^a.

Number of events and at risk by genotype is available in Supplemental Appendix p 9

^b.

Additive genetic models (HR presented per risk allele), unless specified. All models were adjusted for: donor and recipient age, GvHD prophylaxis, use of total body irradiation, and stratified by graft type

^c.

348/404 samples were also genotyped in the DBMT (overlapping set)

^d.

IFNL4 genotype risk allele is defined as the presence of rs368234815-dG allele in NCI set and rs12979860-T allele in DBMT